Teachers Retirement System of The State of Kentucky Has $1.01 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Teachers Retirement System of The State of Kentucky reduced its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 17.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 21,305 shares of the company’s stock after selling 4,612 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Kymera Therapeutics were worth $1,008,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after acquiring an additional 504 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Kymera Therapeutics by 8.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock worth $534,000 after purchasing an additional 915 shares during the period. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics during the third quarter worth $61,000. Arizona State Retirement System grew its stake in shares of Kymera Therapeutics by 15.6% in the second quarter. Arizona State Retirement System now owns 12,830 shares of the company’s stock worth $383,000 after purchasing an additional 1,730 shares during the last quarter. Finally, Handelsbanken Fonder AB increased its holdings in Kymera Therapeutics by 12.3% in the third quarter. Handelsbanken Fonder AB now owns 17,300 shares of the company’s stock valued at $819,000 after purchasing an additional 1,900 shares during the period.

Analysts Set New Price Targets

KYMR has been the topic of several recent research reports. Stephens initiated coverage on Kymera Therapeutics in a report on Monday, November 18th. They set an “overweight” rating and a $65.00 target price on the stock. Oppenheimer lifted their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, September 27th. Guggenheim increased their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Leerink Partners restated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Monday, September 9th. Finally, UBS Group decreased their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.88.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $39.06 on Thursday. The business has a 50-day simple moving average of $46.17 and a 200 day simple moving average of $43.11. Kymera Therapeutics, Inc. has a one year low of $22.35 and a one year high of $53.27. The firm has a market capitalization of $2.53 billion, a price-to-earnings ratio of -16.69 and a beta of 2.16.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same quarter in the previous year, the company posted ($0.90) earnings per share. The company’s quarterly revenue was down 20.9% on a year-over-year basis. On average, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.